FDA Expected To Review Antidepressant Advisory Cmte. Findings At House Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
House Commerce/Oversight Subcommittee convenes Sept. 23 to resume inquiry into antidepressant use in children, methods to handle safety data. FDA may also be questioned on clinical trial registries and off-label promotion.
You may also be interested in...
Antidepressant “Black Box” Warning For Pediatric Suicidality Risk Recommended
“Black box” warning would encourage discussion of risks and benefits of antidepressant therapy in children by physicians, FDA advisory committee members say. Warning likely to affect direct-to-consumer advertising, FDA notes. Committee members recommend class warning for all antidepressants, including new products.
Pediatric Antidepressant Safety: “Jury Is Still Out,” FDA Tells Congress
Discussion of regulatory status of antidepressant indications is almost an afterthought during Sept. 9 House hearing. FDA’s Woodcock, however, stresses that agency is not ready to rule out a role for antidepressants in children.
Off-Label Promotion, Class Labeling Debated During Antidepressant Hearing
The congressional investigation into antidepressants could renew interest in how off-label promotion is regulated in the U.S